The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Association of Immunoglobulin Levels, Infectious Risk, and Mortality With Rituximab and Hypogammaglobulinemia
Open accessAbstract
Importance: Rituximab is an anti-CD20 chimeric antibody used in a wide variety of clinical indications. There has not been widespread adoption of consistent immune monitoring before and after rituximab therapy. However, there is a subset of patients who develop prolonged, symptomatic hypogammaglobulinemia following rituximab, and monitoring before and after rituximab therapy could help to identify these patients and initiate measures to prevent excess morbidity and mortality. Objective: To determine the current levels of screening for hypogammaglobulinemia (specifically, low immunoglobulin G), infectious risks associated with hypogammaglobulinemia, and variables associated with an increased risk of mortality. Design, Setting, and Participants: A cohort study was conducted of 8633 patients receiving rituximab from January 1, 1997, to December 31, 2017, at a large, tertiary referral center (Partners HealthCare System). Exposures: Rituximab administration. Main Outcomes and Measures: The primary outcome measures were immunoglobulin measurements, infectious complications, and mortality. Cox regression analysis was used to examine the results of infectious complications on survival, adjusted for age, sex, and indication for rituximab use. Results: Of the 8633 patients who received rituximab in the large, academic, health care system, 4479 satisfied inclusion criteria, with a mean (SD) age of 59.8 (16.2) years; 2280 patients (50.9%) were women. Most patients (3824 [85.4%]) did not have immunoglobulin levels checked before rituximab therapy. Of those who had levels determined, hypogammaglobulinemia was noted in 313 (47.8%) patients before initiation of rituximab. Following rituximab administration, worsening hypogammaglobulinemia was noted. There was an increase in severe infections after rituximab use in the study cohort (from 17.2% to 21.7%; P < .001). In the survival analysis, increased mortality was associated with increasing age (hazard ratio [HR], 1.02; 95% CI, 1.01-1.02; P < .001), male sex (HR, 1.14; 95% CI, 1.02-1.28; P = .02), and severe infectious complications in the 6 months before (HR, 3.14; 95% CI, 2.77-3.55; P < .001) and after (HR, 4.97; 95% CI, 4.41-5.60; P < .001) the first rituximab infusion. A total of 201 patients (4.5%) received immunoglobulin replacement following rituximab, and among these patients, higher cumulative immunoglobulin replacement dose was associated with a reduced risk of serious infectious complications (HR, 0.98; 95% CI, 0.96-0.99; P = .002). Conclusions and Relevance: Many patients are not being screened or properly identified as having hypogammaglobulinemia both before and after rituximab administration. Monitoring of immunoglobulin levels both before and after rituximab therapy may allow for earlier identification of risk for developing significant infection and identify patients who may benefit from immunoglobulin replacement, which may in turn help to avoid excess morbidity and mortality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cohen, S. B., Emery, P., Greenwald, M. W., Dougados, M., Furie, R. A., Genovese, M. C., Keystone, E. C., Loveless, J. E., Burmester, G., Cravets, M. W., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22025 · Cited by 1,638
(2006) · Arthritis & Rheumatism · doi:10.1002/(issn)1529-0131 · Cited by 530
Mechanisms of killing by anti-CD20 monoclonal antibodies
Glennie, M. J., French, R. R., Cragg, M. S., & Taylor, R. P. (2007) · Molecular Immunology · doi:10.1016/j.molimm.2007.06.151 · Cited by 515
Salliot, C., Dougados, M., & Gossec, L. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.083188 · Cited by 477
Tolerability and safety of rituximab (MabThera®)
Kimby, E. (2005) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2005.05.007 · Cited by 470
Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis
Buch, M. H., Smolen, J. S., Betteridge, N., Breedveld, F. C., Burmester, G., Dörner, T., Ferraccioli, G., Gottenberg, J.-E., Isaacs, J., Kvien, T. K., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.144998 · Cited by 453
Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study
Seymour, J. F., Ma, S., Brander, D. M., Choi, M. Y., Barrientos, J., Davids, M. S., Anderson, M. A., Beaven, A. W., Rosen, S. T., Tam, C. S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30012-8 · Cited by 333
Gottenberg, J. ‐., Ravaud, P., Bardin, T., Cacoub, P., Cantagrel, A., Combe, B., Dougados, M., Flipo, R. M., Godeau, B., Guillevin, L., et al. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27555 · Cited by 305
Casulo, C., Maragulia, J., & Zelenetz, A. D. (2013) · Clinical Lymphoma Myeloma and Leukemia · doi:10.1016/j.clml.2012.11.011 · Cited by 303
Longterm Safety of Patients Receiving Rituximab in Rheumatoid Arthritis Clinical Trials
van VOLLENHOVEN, R. F., EMERY, P., BINGHAM, C. O., KEYSTONE, E. C., FLEISCHMANN, R., FURST, D. E., MACEY, K., SWEETSER, M., KELMAN, A., & RAO, R. (2010) · The Journal of Rheumatology · doi:10.3899/jrheum.090856 · Cited by 287
Mayor, P. C., Eng, K. H., Singel, K. L., Abrams, S. I., Odunsi, K., Moysich, K. B., Fuleihan, R., Garabedian, E., Lugar, P., Ochs, H. D., et al. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.05.024 · Cited by 247
Chase, N. M., Verbsky, J. W., Hintermeyer, M. K., Waukau, J. K., Tomita-Mitchell, A., Casper, J. T., Singh, S., Shahir, K. S., Tisol, W. B., Nugent, M. L., et al. (2013) · Journal of Clinical Immunology · doi:10.1007/s10875-012-9755-3 · Cited by 192
How I treat autoimmune hemolytic anemia
Go, R. S., Winters, J. L., & Kay, N. E. (2017) · Blood · doi:10.1182/blood-2016-11-693689 · Cited by 189
Roll, P., Dörner, T., & Tony, H. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23473 · Cited by 187
Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies
Taylor, R. P., & Lindorfer, M. A. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.05.011 · Cited by 155
How I treat refractory immune thrombocytopenia
Cuker, A. C., & Neunert, C. E. (2016) · Blood · doi:10.1182/blood-2016-03-603365 · Cited by 154
Hypogammaglobulinaemia after rituximab treatment--incidence and outcomes
Makatsori, M., Kiani‐Alikhan, S., Manson, A. L., Verma, N., Leandro, M. J., Gurugama, N. P., Longhurst, H. J., Grigoriadou, S., Buckland, M. S., Kanfer, E., et al. (2014) · QJM · doi:10.1093/qjmed/hcu094 · Cited by 144
Nakou, M., Katsikas, G., Sidiropoulos, P. I., Bertsias, G. K., Papadimitraki, E. D., Raptopoulou, A., Koutala, H., Papadaki, H. Α., Kritikos, H. D., & Boumpas, D. T. (2009) · Arthritis Research & Therapy · doi:10.1186/ar2798 · Cited by 136
Risk factors predisposing to the development of hypogammaglobulinemia and infections post-Rituximab
Christou, E. A. A., Giardino, G., Worth, A. J. J., & Ladomenou, F. (2017) · International Reviews of Immunology · doi:10.1080/08830185.2017.1346092 · Cited by 110
Rituximab and Immune Deficiency: Case Series and Review of the Literature
Kaplan, B. M., Kopyltsova, Y., Khokhar, A., Lam, F., & Bonagura, V. R. (2014) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2014.06.003 · Cited by 109
Farmer, J. R., Ong, M., Barmettler, S., Yonker, L. M., Fuleihan, R., Sullivan, K. E., Cunningham‐Rundles, C., & Walter, J. E. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01740 · Cited by 87
Self-citationCortazar, F. B., Pendergraft, W. F., Wenger, J., Owens, C. T., Laliberte, K. A., & Niles, J. L. (2016) · Arthritis & Rheumatology · doi:10.1002/art.40032 · Cited by 83
Roberts, D. M., Jones, R. B., Smith, R., Alberici, F., Kumararatne, D. S., Burns, S., & Jayne, D. R. W. (2015) · Journal of Autoimmunity · doi:10.1016/j.jaut.2014.11.004 · Cited by 79
Kado, R., Sanders, G., & McCune, W. J. (2017) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000377 · Cited by 44
Cited by
CAR T-cell therapy in autoimmune diseases
Schett, G., Mackensen, A., & Mougiakakos, D. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01126-1 · Cited by 430
Lancman, G., Parsa, K., Kotlarz, K., Avery, L., Lurie, A., Lieberman-Cribbin, A., Cho, H. J., Parekh, S. S., Richard, S., Richter, J., et al. (2023) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-23-0049 · Cited by 140
Metadata
- Authors
- Barmettler, S., Ong, M.-S., Farmer, J. R., Choi, H., & Walter, J.
- Venue
- JAMA Network Open
- Publisher
- American Medical Association (AMA)
- Published
- 2018-11-02
- Volume
- 1
- Issue
- 7
- Pages
- e184169
- ISSN
- 2574-3805 (ISSN-L)
- OpenAlex
- W2900348232
- Cited by
- 357
- References
- 24
- FWCI
- 8.90
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.